Kolexia
Schlurmann Friederike Oncologie médicale
Schlurmann Friederike
Oncologie médicale
Hôpital Morvan
Brest, France
191 Activités
189 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Carcinomes Néphrocarcinome Tumeurs prostatiques résistantes à la castration Tumeurs du rein Hypertension artérielle Complications peropératoires Tumeurs embryonnaires et germinales Métastase tumorale

Collaborateurs

Voir plus
Pignot Geraldine
Pignot Geraldine
Centre Paoli-Calmettes, Marseille, France
Barthelemy Philippe
Barthelemy Philippe
Hôpital Civil, Strasbourg, France
Valeri Antoine
Valeri Antoine
Hôpital Cavale Blanche, Brest, France
Supiot Stephane
Supiot Stephane
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
MSD
48 collaboration(s)
Dernière en 2023
AstraZeneca
34 collaboration(s)
Dernière en 2023
Janssen
28 collaboration(s)
Dernière en 2023
BMS
27 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer: A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Essai Clinique (MacroGenics)   18 mars 2024
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)
Essai Clinique (AstraZeneca)   02 février 2024
PEACE1: A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Essai Clinique (Ipsen)   07 novembre 2023
Néphrectomies « de clôture » post-immunothérapie: facteurs prédictifs de complications peropératoires
117e congrès français d'urologie   01 novembre 2023
1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
The Lancet. Oncology   12 septembre 2023
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable): A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Essai Clinique (Bayer)   10 mai 2023
New drugs approval: Lutetium-PSMA in metastatic castration-resistant prostate cancer.
Bulletin du cancer   12 avril 2023
Spécificités cliniques des tumeurs de vessie n’infiltrant pas le muscle métastatique d’emblée : étude observationnelle multicentrique merinos
116e congrès français d'urologie   01 novembre 2022
157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Abstract Book of the ESMO Asia Congress 2022 2-4 December 2022.   01 novembre 2022